Brian Joondeph, MD
Retina Specialist · Denver, CONPI 1932151230
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (52.4%), ownership interests and consulting fees — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by AbbVie at 27.6% of the total. Reporting peaked in 2019 at $36,327 and has fallen 97.6% since, to $887 in 2025. Among retina specialist clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 274 payments — averaging $335.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$25K
- Novartis$25K
- US Retina LLC$20K
- Biogen$15K
- Vertex$1K
- Alcon$1K
- plus $5K from 19 others
Across 26 payments — averaging $56,194 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$1.4M
- Astellas Pharma Global Development$39K
- Eyepoint US, Inc.$26K
What the payments were for
- Consulting fees$8,5159%
- Speaking & faculty fees$48,25052%
- Grants$830%
- Travel & lodging$6,9858%
- Food & beverage$7,2998%
- Education$7501%
- Gifts$190%
- Entertainment$860%
- Ownership interest$18,27420%
- Other$1,7692%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 70 | $25,427 |
| Novartis | 40 | $24,667 |
| US Retina LLC | 8 | $20,042 |
| Biogen | 23 | $14,803 |
| Vertex | 3 | $1,207 |
| Alcon | 4 | $1,042 |
| Regeneron Healthcare Solutions, Inc. | 33 | $1,025 |
| Genentech, Inc. | 5 | $746 |
| Genentech USA, Inc. | 27 | $523 |
| Astellas Pharma US Inc | 12 | $517 |
| Alimera Sciences, Inc. | 7 | $366 |
| Eyepoint US, Inc. | 7 | $339 |
| Coherus Oncology, Inc. | 9 | $220 |
| Cardinal Health 110 LLC | 1 | $150 |
| Apellis Pharmaceuticals, Inc. | 6 | $147 |
| Regeneron | 1 | $134 |
| Bausch & Lomb Americas Inc. | 5 | $122 |
| Topcon Healthcare, Inc. | 1 | $104 |
| ANI Pharmaceuticals, Inc. | 4 | $92 |
| Optos, Inc. | 1 | $86 |
| Heidelberg Engineering, Inc. | 1 | $76 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $75 |
| Harrow Eye, LLC | 3 | $63 |
| Mallinckrodt Hospital Products Inc. | 1 | $35 |
| Carl Zeiss Meditec AG | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$92,029 in reported general payments places this provider in the 95th percentile of 51 retina specialist providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 41 | $1,532 |
| Ketorolac Tromethamine | 55 | $1,529 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 36 | $447 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 14 | $160 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Denver
- Alan KimuraDenver$546K
- Nancy ChristmasDenver$12K
- Jesse SmithDenver$7K
- Miriah TeeterDenver$3K
- Diana ReevesDenver$3K
- Mariana HarasawaDenver$332
- Murtaza AdamParker$548K
- Talisa ForestAurora$84K
- Sara HaugDurango$59K
- Matthew ManryLongmont$43K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.